NCT02752516View on ClinicalTrials.gov

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Cancer
Interventions
DRUG

Anlotinib

Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY